anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
OBJECTIVES: I. Evaluate the complete response rate to combination fludarabine, idarubicin, and cytarabine in children with relapsed or refractory acute lymphocytic leukemia. II. Evaluate the safety and tolerance of this treatment in these patients. III. Evaluate the time to progression, disease free survival, and overall survival of these patients.

OUTLINE: This is an open label, multicenter study. Patients receive idarubicin IV over 1 hour on days 1-3. Fludarabine IV is administered over 30 minutes on days 1-5. Cytarabine IV is administered over 4 hours on days 1-5. If partial response is obtained, patients receive a second course of treatment. Patients receive a consolidation course in the absence of disease progression and unacceptable toxicity. Idarubicin IV is administered over 1 hour on days 1 and 2. Fludarabine IV is administered over 30 minutes, followed by cytarabine IV over 4 hours on days 1-5. Patients are followed every 3 months for 2 years or until death.

PROJECTED ACCRUAL: A total of 24-45 patients will be accrued for this study within 27 months.
Participants who received SC TCZ will continue at their same dosage of SC TCZ 162 mg Q2W. Tocilizumab will be given for an additional 96 weeks in this open-label extension study.
BACKGROUND/AIM: Thoracic paravertebral block (TPVB) is a well-established procedure for the management of postoperative pain in patients undergoing video-assisted thoracic surgery (VATS). In recent years, there have been studies suggesting that fascial plane blocks may be an alternative to TPVB. The objective of our study was to determine the efficacy of combined deep and superficial serratus anterior block (C-SAPB) as an alternative to TPVB in the management of postoperative analgesia in VATS.
MATERIALS AND METHODS: The patients were divided into two groups: the TPVB group and the C-SAPB group. Both groups were administered the same dose of local anesthetics. Multimodal analgesia was achieved for the groups. The primary outcome measure was visual analog scale (VAS) pain scores recorded within the first 48 h of the postoperative period in each group. The secondary outcomes were analgesic requirement, rescue analgesics, complications rate, and postoperative patient satisfaction.
RESULTS: Thirty patients with C-SAPB and 30 patients with TPVB were analysed. VAS rest and VAS coughing scores were similar between the groups (p > 0.05). Demographic and side effect conditions, total morphine use, additional analgesic needs, vital parameters, block procedure time, and patient satisfaction were also similar between the groups (p > 0.05). Additionally, although block application times were comparable, the time was slightly shorter in C-SAPB.
CONCLUSION: Similar analgesic efficacy was observed between C-SAPB and TPVB. TPVB maintains its place among the first choices in VATS. The efficacy of C-SAPB is comparable to that of TPVB. While the duration of C-SAPB application is not a significant factor, the brief nature of the procedure and its straightforward administration suggest that it may be an effective method.
BACKGROUND: Toxic shock syndrome (TSS) is a rare but potentially life-threatening disease caused by superantigen-producing Gram-positive bacteria such as Staphylococcus aureus and Streptococcus pyogenes. Staphylococcal TSS received special attention from 1978 to 1981, when an epidemic was observed associated with the use of hyper-absorbent tampons. Today the disease is rare and generally not related to menstruation, but can occur postpartum or in post-surgical wounds, intrauterine devices (IUDs), burns or other soft tissue injuries, mastitis or other focal infections. The annual incidence of staphylococcal TSS is around 0.5/100 000 and around 0.4/100 000 for streptococcal TSS. The mortality in menstrual-related cases is < 5 % and up to 22 % in non-menstrual related cases.
CASE PRESENTATION: This article presents a case of a middle-aged woman who developed symptoms of toxic shock syndrome five days after elective breast cancer surgery, with high fever, multiorgan failure and a characteristic desquamation of the palms.
INTERPRETATION: Toxic shock syndrome is a potentially lethal, toxin-mediated disease. Symptoms develop quickly, within hours. Early recognition and appropriate surgical management, intensive care and antibiotics are therefore important to reduce mortality and sequelae.
In patients with upper urinary tract bleeding, aminocaproic acid administration has been known to cause intrarenal obstruction in the form of glomerular capillary thrombosis or clots in the renal pelvis and ureters. For this reason, aminocaproic acid should not be used in hematuria of upper urinary tract origin, unless the possible benefits outweigh the risk. 

Subendocardial hemorrhages have been observed in dogs given intravenous infusions of 0.2 times the maximum human therapeutic dose of aminocaproic acid and in monkeys given 8 times the maximum human therapeutic dose of aminocaproic acid. 

Fatty degeneration of the myocardium has been reported in dogs given intravenous doses of aminocaproic acid at 0.8 to 3.3 times the maximum human therapeutic dose and in monkeys given intravenous doses of aminocaproic acid at 6 times the maximum human therapeutic dose.

Rarely, skeletal muscle weakness with necrosis of muscle fibers has been reported following prolonged administration. Clinical presentation may range from mild myalgias with weakness and fatigue to a severe proximal myopathy with rhabdomyolysis, myoglobinuria, and acute renal failure. Muscle enzymes, especially creatine phosphokinase (CPK) are elevated. CPK levels should be monitored in patients on long-term therapy. Aminocaproic acid administration should be stopped if a rise in CPK is noted. Resolution follows discontinuation of aminocaproic acid; however, the syndrome may recur if aminocaproic acid is restarted. 

The possibility of cardiac muscle damage should also be considered when skeletal myopathy occurs. One case of cardiac and hepatic lesions observed in man has been reported. The patient received 2 g of aminocaproic acid every 6 hours for a total dose of 26 g. Death was due to continued cerebrovascular hemorrhage. Necrotic changes in the heart and liver were noted at autopsy.
The invention provides a traditional Chinese medicine formula for preserving health and treating multiple diseases. The traditional Chinese medicine formula disclosed by the invention comprises 60 medicinal materials. The medicinal materials of the formula are smashed and are fully mixed; and medicinal powder is processed into tablets, prills and capsules. The traditional Chinese medicine formula is on the basis of the holistic view of the traditional Chinese medicine and has good effects of nourishing qi and blood, dredging meridians, tonifying spleen, soothing liver, reinforcing kidney, regulating and replenishing yin and yang as well as appropriately regulating and replenishing the vital organs of the human body. The medicine of the formula has good effects of preserving health, building body, promoting longevity and delaying senility, lightening body, beautifying, removing freckles and whitening skins after being used for a long time. The formula can be used for preventing and treating cardiovascular and cerebrovascular diseases and gynecological endocrinology.
The present invention provides improved artificial blood fluids and microflow drag reducing factors for use in such fluids as well as the restoration and/or enhancement of microcirculation and tissue oxygenation. In accordance with preferred embodiments, artificial blood fluids with synthetic or natural oxygen carrying compounds are improved through the inclusion of small amounts of blood soluble microflow drag reducing factors. Microflow drag reducing factors may be combined with physiologically acceptable carriers to form fluids for the restoration and/or enhancement of microcirculation and tissue oxygenation. Physiologically acceptable carriers are preferred as those having a polyethylene glycol adjuvant. The concentration of microflow drag reducing factor is from about 0.1 ppm to about 10,000 ppm by weight of the blood fluid. Certain embodiments feature the employment of certain third and fourth generation dendritic polymers to improve emulsification of artificial blood fluids.
Xenon Xe 133 is a readily diffusible gas which is neither utilized nor produced by the body. It passes through cell membranes and freely exchanges between blood and tissue. It tends to concentrate more in body fat than in blood, plasma, water or protein solutions. In the concentrations used for diagnostic purposes it is physiologically inactive. Inhaled Xenon Xe 133 Gas will enter the alveolar wall and enter the pulmonary venous circulation via the capillaries. Most of the Xenon Xe 133 that enters the circulation from a single breath is returned to the lungs and exhaled after a single pass through the peripheral circulation.
PROBLEM TO BE SOLVED: To obtain a medicinal composition which is excellent in adhesion and retention of the medicine without tackiness to sufficiently manifest its medicinal effect by formulating a silica powder together with a water-repellent polymer as a base. SOLUTION: This medicinal composition is prepared by formulating a medicinal component to a base material comprising (A) a volatile oil component, preferably in an amount of 20-60wt.%, (B) a water-repellent polymer soluble in the oil component, preferably in an amount of 5-20%, (C) a powder which can be coated with a water-repellent polymer in the absence of the oil component (silica is particularly suitable), preferably in an amount of 1-10wt.%, (D) a non-volatile oil compatible to the volatile oil, preferably in an amount of 5-30wt.%. The volatile oil is a volatile silicone oil and the water-repellent polymer is preferably a silicone resin. The weight ratio of the water-repellent polymer to the non-volatile oil is preferably 1/2-2/1. The non-volatile oil is, for example, liquid paraffin, squalane and the like.  The medicine is, for example, an antipyretics analgesic, an analgesic, an antipruritic, an astringent and an anti-inflammatory.
FIELD: food-processing industry. SUBSTANCE: edible product has thin inorganic film of 0.0002-0.5 micron thickness applied to at least part of product surface. Edible products include food products and pharmaceuticals. Inorganic materials used in cover include SiO 2 , SiO, MgO, CaO, TiO 2 , and MnO. Method involves depositing film of inorganic material by spraying or vapor deposition. Cover forms moisture and oxygen barrier to provide for improved storage life of covered edible product. EFFECT: improved quality of edible product and reduced consumption of packing material. 26 cl, 8 dwg, 5 ex
A within school randomized control trial intervention design will be implemented to promote intergroup relationships and reduce prejudice in childhood for children between 7 and 12 years of age, enrolled in grades 3, 4, and 5 in U.S. elementary public schools. The intervention students watch an online tool for 15 minutes accompanied by a 30-minute teacher-led classroom discussion. Students in the control condition will be business as usual. There will be 720 students and 36 teachers, reflecting an ethnically diverse population. The outcome measures assess school belonging, peer and teacher classroom support, trait attributions of diverse peers, social evaluations about intergroup exclusion as well as the likelihood of exclusion, and math and science competency beliefs of diverse peers. All teachers participate in a 2-hour training session prior to the start of the school semester. All participating students have active parental consent. All teachers take a survey about their theories of prejudice, awareness of student experiences with exclusion, and strategies for talking about peer conflict in the classroom prior to the beginning of the program and provide their assent. There is high fidelity of the program due to the delivery of the information which is online. There are many steps in place to ensure fidelity of the teacher component which involves leading the classroom discussion. Multi-level analyses will be employed to determine whether the students in the intervention improve in their desire for intergroup friendships and experiences of classroom support relative to the students in the control condition. Novel data will be collected regarding intergroup attitudes held by children across a range of target groups and grade levels. The information from this project is expected to improve peer relationships due to the more positive classroom environment and an increase of social inclusion among peers. All children are expected to benefit by their participation in the program with a goal of improving academic engagement and healthy child development.
PURPOSE: Provided is a toothpaste containing colloidal silver which inflicts no harm on the health of people and shows effective anti-bacterial effects, and contributing to healthy teeth. CONSTITUTION: The toothpaste contains colloidal silver whose silver ions are dissolved in distilled water. Silver particles in the colloidal solution have the particle size of between 0.001μm and 0.02μm. And abrasives include dicalcium phosphate dihydrate, calcium carbonate etc. Binding agents are carboxy methyl cellulose sodium, carrageenan, xanthan gum, and polyacrylic acid and base. Wetting agents are selected form sorbitol solution, glycerin, polyethylene glycol, and propylene glycol. Alkyl sodium sulfate, anion surfactant, is used as a frothing agent.
In the prodn. of monovalent blocking antibodies of antibody fragments against growth-regulating substances and cell-membrane receptors by active immunisation of antibody-forming individuals with organ or cell homogenates or extracts or factors obtd. from them (e.g. growth factors from thymus, saliva glands etc., growth-inhibiting factors such as organ-specific chalones, or receptors for hormones, tissue hormones or drugs), the antibodies or antibody fragments are isolated from the urine by ion-exchange chromatography, gel filtration, membrane filtration and centrifugation, opt. after treatment with drugs which at an appropriate dosage cause an increase in physiological proteinuria (e.g. nephrotoxic agents, homeopathic agents and/or diuretics). The antibodies and antibody fragments are useful therapeutically for e.g. gene activation, stimulation of synthetic processes, antagonising growth-promoting agents (e.g. in cancer), and for inactivating or stimulating receptors.
OBJECTIVE: To assess the effect and safety of electrothermal acupuncture in adjunctive treatment of stable chronic obstructive pulmonary disease (COPD) in patients.
METHODS: Sixty-six stable COPD patients were randomly divided into an observation group and a control group, with 33 cases in each group. The patients in the control group were treated with bronchodilator inhalation combined with respiratory training for 4 weeks. In the observation group, on the basis of the treatment as the control group, electrothermal acupuncture was delivered at bilateral Quchi (LI 11), Zusanli (ST 36) and Sanyinjiao (SP 6), and the conventional filiform needling was operated at the supplementary acupoints selected according to the individual syndrome. The interventions in the observation group were given once every two days, 3 treatments a week, for consecutive 4 weeks. Before and after treatment completion, the lung functions (forced expiratory volume in the first second [FEV1], forced vital capacity [FVC], FEV1/FVC and the percentage of diffusing capacity of the lungs for carbon monoxide [DLCO%]), 6 min walking distance (6MWD) and the score of COPD assessment test (CAT) were compared between the two groups. The attacks of acute exacerbation were recorded in 1-year follow-up visit in the two groups and the safety of electrothermal acupuncture was evaluated.
RESULTS: After treatment, FEV1, FVC, FEV1/FVC, DLCO% and 6MWD were increased (P<0.01, P<0.05), and CAT scores were decreased (P<0.01) in the two groups compared with those before treatment. FEV1, FVC, FEV1/FVC and 6MWD were higher and CAT score was lower in the observation group when compared with those of the control group (P<0.05). In the 1-year follow-up visit, the cases of acute exacerbation in the observation group were fewer than that in the control group (P<0.05). There were no treatment-related adverse reactions in the observation group.
CONCLUSION: On the basis of bronchodilator inhalation and respiratory training, electrothermal acupuncture can ameliorate the lung function, strengthen motor ability, reduce the cases of acute exacerbation safely and effectively in the patients with stable COPD.
The application discloses a data processing method and a non-small cell lung cancer brain metastasis risk prediction system. The brain metastasis prediction system at least comprises a detection unit, a model screening unit and a risk prediction unit. The detection unit acquires pathology data associated with a lesion of non-small cell lung cancer and detects target gene data therefrom, and the detection unit further comprises a first data screening subunit adapted to determine a plurality of candidate biomarker data. The model screening unit respectively processes the candidate biomarker data by utilizing a plurality of candidate prediction models to predict risk values, and selects a prediction model according to the prediction effect of each candidate prediction model. The first data screening subunit also selects a predetermined number of candidate biomarker data as first biomarker data using the predictive model. The risk prediction unit processes the first biomarker data by using a prediction model and outputs a risk value. The system can accurately predict the focus brain metastasis of the non-small cell lung cancer.
Two MI sessions focusing on stimulant use, sexual risk, and PrEP use will be delivered. Participants who do not fill a PrEP prescription at 3 months will receive CM financial incentives for PrEP clinical evaluation and filling a PrEP prescription.
PURPOSE: To obtain the subject differentiating agent containing an active ingredient selected from a substance having a neurotrophic factor activity and a substance capable of promoting production of the factor in vivo and useful as a medicine for treating thrombocytopenia and diseases accompanied by lowering of platelet function. CONSTITUTION: This differentiating agent contains at least one kind of a substance having a neurotrophic factor(NF) activity (preferably human NF such as a human nerve growth factor) and a substance promoting production of NF in in vivo (e.g. epinephrine or 4-methyl catechol) as an active ingredient. The differentiating agent is preferably administered by injection and the daily dose is preferably 0.2μg/kg to 2mg/kg as a protein amount when human nerve growth factor is administered by injection. It is preferable from the view point of storage stability, etc., to use the differentiating agent as a form of frozen and dried article.  The differentiating agent is blended with a human serum albumin used as a stabilizer in order to prevent lowering of activity and the agent is blended with a cytokinin such as interleukin-1 in order to improve megakaryocyte proliferating and differentiating effect.
A method of combatting colour lass in a dyed material, the method comprising the steps of: (1) contacting the material with a composition comprising an electrophilic species selected from aldehydes, succinimidyl esters, and mixtures thereof; (2) contacting the material with a composition comprising a chelating agent and/or a salt of an amine and a carboxylic acid. The material is preferably a keratinous material, particularly wool; human or animal hair. Step (1) may be performed before, after or simultaneously with step (2), particularly wherein steps (1) and (2) are simultaneous the components are provided in a single composition. A method of colouring hair comprising the steps (a) contacting the hair with a colouring composition in conjunction with the prior method (b), wherein the steps may be performed in either order or simultaneously. Hair care compositions comprising an electrophilic species selected from aldehydes, succinimidyl esters, and mixtures thereof and a chelating agent and/or a salt of an amine and a carboxylic acid and packaged products comprising the same are also disclosed. The aldehyde is preferably selected from alpha-hydroxy aldehydes, such as 2-hydroxydecanal, 2-hydroxyoctanal and glyceraldehyde. The chelating agent is preferably a polycarboxylic acid, particularly N,N-bis(carboxymethyl)-L-glutamic acid (GLDA) or diethylenetriaminepentaacetic acid (DTPA).
Endodontic diseases are a kind of chronic infectious oral disease. Common endodontic treatment concepts are based on the removal of inflamed or necrotic pulp tissue and the replacement by gutta-percha. However, it is very essential for endodontic treatment to debride the root canal system and prevent the root canal system from bacterial reinfection after root canal therapy (RCT). Recent research, encompassing bacterial etiology and advanced imaging techniques, contributes to our understanding of the root canal system's anatomy intricacies and the technique sensitivity of RCT. Success in RCT hinges on factors like patients, infection severity, root canal anatomy, and treatment techniques. Therefore, improving disease management is a key issue to combat endodontic diseases and cure periapical lesions. The clinical difficulty assessment system of RCT is established based on patient conditions, tooth conditions, root canal configuration, and root canal needing retreatment, and emphasizes pre-treatment risk assessment for optimal outcomes. The findings suggest that the presence of risk factors may correlate with the challenge of achieving the high standard required for RCT. These insights contribute not only to improve education but also aid practitioners in treatment planning and referral decision-making within the field of endodontics.
Facial expressions of pain play an important role in pain diagnostics and social interactions. Given the prominent impact of sex on various aspects of pain, it is not surprising that sex differences have also been explored regarding facial expressions of pain; however, with inconclusive findings. We aim to further investigate sex differences in facial expressions of pain by using a large, combined sample to maximize statistical power. Data from 7 previous studies of our group were merged, combining in total the data of 392 participants (male: 192, female: 200). All participants received phasic heat pain, with intensities being tailored to the individual pain threshold. Pain intensity ratings were assessed, and facial responses were manually analyzed using the Facial Action Coding. To compare facial and subjective responses between sexes, linear mixed-effects models were used, with study ID as a random effect. We found significant sex differences in facial responses, with females showing elevated facial responses to pain, although they received lower physical heat intensities (women had lower pain thresholds). In contrast, pain intensity ratings did not differ between sexes. Additionally, facial and subjective responses to pain were significantly associated across sexes, with females showing slightly stronger associations. Although variations in facial expressions of pain are very large even within each sex, our findings demonstrate that women facially communicate pain more intensively and with a better match to their subjective experience compared with men. This indicates that women might be better in using facial communication of pain in an intensity-discriminative manner.